294 related articles for article (PubMed ID: 18078434)
1. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation.
Tanaka H; Hashimoto N
Cardiovasc Drug Rev; 2007; 25(4):342-56. PubMed ID: 18078434
[TBL] [Abstract][Full Text] [Related]
2. NIP-141, a multiple ion channel blocker, terminates aconitine-induced atrial fibrillation and prevents the rapid pacing-induced atrial effective refractory period shortening in dogs.
Hashimoto N; Yamashita T; Fujikura N; Tsuruzoe N
Europace; 2007 Apr; 9(4):246-51. PubMed ID: 17350982
[TBL] [Abstract][Full Text] [Related]
3. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat.
de Haan S; Greiser M; Harks E; Blaauw Y; van Hunnik A; Verheule S; Allessie M; Schotten U
Circulation; 2006 Sep; 114(12):1234-42. PubMed ID: 16940189
[TBL] [Abstract][Full Text] [Related]
4. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide.
Hashimoto N; Yamashita T; Tsuruzoe N
J Cardiovasc Pharmacol; 2008 Feb; 51(2):162-9. PubMed ID: 18287884
[TBL] [Abstract][Full Text] [Related]
5. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs.
Li GR; Wang HB; Qin GW; Jin MW; Tang Q; Sun HY; Du XL; Deng XL; Zhang XH; Chen JB; Chen L; Xu XH; Cheng LC; Chiu SW; Tse HF; Vanhoutte PM; Lau CP
Circulation; 2008 May; 117(19):2449-57. PubMed ID: 18458165
[TBL] [Abstract][Full Text] [Related]
6. Vernakalant hydrochloride for the treatment of atrial fibrillation.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
[TBL] [Abstract][Full Text] [Related]
7. Dronedarone.
Patel C; Yan GX; Kowey PR
Circulation; 2009 Aug; 120(7):636-44. PubMed ID: 19687370
[TBL] [Abstract][Full Text] [Related]
8. Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter.
Nagasawa H; Fujiki A; Fujikura N; Matsuda T; Yamashita T; Inoue H
Circ J; 2002 Feb; 66(2):185-91. PubMed ID: 11999646
[TBL] [Abstract][Full Text] [Related]
9. Theoretical possibilities for the development of novel antiarrhythmic drugs.
Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
[TBL] [Abstract][Full Text] [Related]
10. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.
Ravens U; Wettwer E
Cardiovasc Res; 2011 Mar; 89(4):776-85. PubMed ID: 21159668
[TBL] [Abstract][Full Text] [Related]
11. Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange.
Schotten U; de Haan S; Verheule S; Harks EG; Frechen D; Bodewig E; Greiser M; Ram R; Maessen J; Kelm M; Allessie M; Van Wagoner DR
Cardiovasc Res; 2007 Jan; 73(1):37-47. PubMed ID: 17157284
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
Kirchhof P; Engelen M; Franz MR; Ribbing M; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
Basic Res Cardiol; 2005 Mar; 100(2):112-21. PubMed ID: 15696400
[TBL] [Abstract][Full Text] [Related]
13. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
14. Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium.
Matsuda T; Takeda K; Ito M; Yamagishi R; Tamura M; Nakamura H; Tsuruoka N; Saito T; Masumiya H; Suzuki T; Iida-Tanaka N; Itokawa-Matsuda M; Yamashita T; Tsuruzoe N; Tanaka H; Shigenobu K
J Pharmacol Sci; 2005 May; 98(1):33-40. PubMed ID: 15879679
[TBL] [Abstract][Full Text] [Related]
15. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of electrical remodeling in atrial fibrillation.
Van Wagoner DR; Nerbonne JM
J Mol Cell Cardiol; 2000 Jun; 32(6):1101-17. PubMed ID: 10888261
[TBL] [Abstract][Full Text] [Related]
17. The effects of 5-HT4 receptor blockade and stimulation, during six hours of atrial fibrillation.
Leftheriotis DI; Theodorakis GN; Poulis D; Flevari PG; Livanis EG; Iliodromitis EK; Papalois A; Kremastinos DT
Europace; 2005 Nov; 7(6):560-8. PubMed ID: 16216758
[TBL] [Abstract][Full Text] [Related]
18. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
Pecini R; Elming H; Pedersen OD; Torp-Pedersen C
Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
[TBL] [Abstract][Full Text] [Related]
19. In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling.
Tsujimae K; Murakami S; Kurachi Y
Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H793-800. PubMed ID: 18055524
[TBL] [Abstract][Full Text] [Related]
20. Inward rectifier potassium currents as a target for atrial fibrillation therapy.
Ehrlich JR
J Cardiovasc Pharmacol; 2008 Aug; 52(2):129-35. PubMed ID: 18670367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
